Y-Biologics, Inc. (KOSDAQ: 338840)

Market Cap	158.92B
Revenue	n/a
Net Income	n/a
Shares Out	14.77M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,045,137
Open	11,280
Previous Close	11,270
Day's Range	10,600 - 11,520
52-Week Range	7,570 - 23,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Y-Biologics

Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers. Y-Biologics, Inc. was incorporated in 2007 and is headquar...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 338840